A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
NCT05442554
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
T-Cell Lymphoma
Interventions
DRUG:
Brentuximab vedotin
Sponsor
Takeda